Almirall
Three products with almost nothing in common except a habit of printing the boundary of what is known — a legacy retinoid that publishes what happened twelve weeks after people stopped, an oral antibiotic that caps its own evidence at twelve weeks, and a five-day course that ends.
MODEL
New Drug Applications and acquired brands, manufactured products, retail pharmacy dispensing on a prescriber's script.
The brand verdict
This is a mixed portfolio rather than a coherent range: a 1990s tazarotene cream, a purpose-built narrow-spectrum tetracycline, and a microtubule inhibitor for actinic keratosis. What they share is that each one publishes the point at which its evidence runs out, which across this register is the exception rather than the rule.
Tazorac is the register's cleanest natural experiment. It is the same molecule as Arazlo at R-37, at twice the strength and a tenth of the price, reporting irritation in 10 to 30% of acne subjects against Arazlo's 4 to 5%. All the difference is the vehicle. It also carries the only post-treatment measurement in this register: clinical success at week 24, three months after the last application, at 33% and 30% against 22% on vehicle.
Seysara's contribution is a limitations-of-use section that states four separate things the drug has not been shown to do — efficacy beyond twelve weeks, safety beyond twelve months, any use in infection, and the resistance instruction. It is the second considered answer in this register to the antibiotic problem, alongside Oracea at R-48, and the two answers are different: narrow the spectrum and cap the course, or drop the dose below the antibacterial threshold entirely.
Klisyri is the best of the three and the most unusual product here. Five days of treatment from unit-dose packets, complete 100% clearance as the primary endpoint, 44% and 54% against 5% and 13% on vehicle, and a trial population with an average age of 70. It also closes a gap this register opened at R-34, where the only approved photoageing product excluded patients with actinic keratosis from its own evidence base.
- Tazorac publishes results twelve weeks after treatment stopped — the only post-treatment data in this register.
- Tazorac publishes both strengths with their own trial results, and states that the stronger one is more irritating.
- Tazorac prints the full six-point lesional assessment scale, so 'clinical success' is checkable.
- Seysara's limitations of use state four separate things the drug has not been shown to do.
- Seysara caps its own evidence at twelve weeks in the indication itself.
- Seysara carries a direct antibiotic-stewardship instruction.
- Seysara's trial population was 51% adults and 15% Black or African American.
- Klisyri uses complete 100% clearance as its primary endpoint, not partial improvement.
- Klisyri reports face and scalp results separately rather than pooling them.
- Klisyri collects local skin reactions independently of adverse events and publishes them by severity.
- Klisyri followed subjects who cleared for twelve months to measure recurrence.
- Klisyri ships as unit-dose packets, so the dose is set by the packaging rather than the patient.
The range
- R-542026-08-02
Klisyri
TIRBANIBULIN OINTMENT 1%Five days of treatment, then you stop. Complete clearance of actinic keratoses in 44% and 54% of subjects against 5% and 13% on vehicle — and it answers a question R-34 raised and left hanging, because these are the photodamaged patients every anti-ageing trial excluded.
RECOMMENDED$281 FIVE DAYS
- R-532026-08-02
Seysara
SARECYCLINE 60 / 100 / 150 MGA tetracycline engineered narrow, dosed by body weight, with a label that says efficacy beyond twelve weeks has not been established and that it must not be used for infection. The second considered answer in this register to the antibiotic problem — and the effect size is 22%.
CONDITIONAL$262 PER 30 TABLETS
- R-512026-08-02
Tazorac
TAZAROTENE CREAM 0.05% AND 0.1%The same molecule as R-37 at twice the strength and a tenth of the price, with irritation reported in 10 to 30% of users instead of 4 to 5%. It is also the only retinoid in this register with published data twelve weeks after people stopped using it.
CONDITIONAL$53 PER TUBE
What repeats across the range
These are the findings a single review cannot make. Each one appears in more than one product, and each is drawn from the reviews above rather than from an impression of the brand.
- 01
Each label states where the evidence stops
Seysara: efficacy beyond twelve weeks and safety beyond twelve months not established. Tazorac: the stronger cream is more effective and more irritating. Klisyri: local skin reactions published by severity grade, and a warning that severe reactions including ulceration can occur. Three products, three boundaries printed rather than implied.
- 02
The only post-treatment data in the register
Tazorac's first psoriasis trial kept measuring for twelve weeks after treatment stopped and published a durable result — 33% and 30% still clinically successful against 22% on vehicle. Renova says effects may be lost within twelve weeks of stopping. Tri-Luma says melasma usually recurs. No compounded product here has measured it at all.
- 03
Two products that end
Klisyri is five packets and then nothing. Seysara's label caps its own evidence at twelve weeks. In a register where the great majority of products state no duration at all and several are sold on rolling monthly billing, two out of three is a notable ratio.
- 04
Local skin reactions collected independently of adverse events
Klisyri reports erythema worse than baseline in 91% of subjects while the volunteered adverse reaction list records only local skin reactions, pruritus and pain at 2% or more. Aklief at R-50 does the same thing, and between them the two labels establish that a volunteered irritation rate is a floor rather than an estimate.
- 05
The prices bear no relation to the molecules
Tazorac from around $53, with generic tazarotene near $40. Klisyri from $281 against an average retail near $1,944. Seysara from $262 against an average retail near $1,322. Two of the three carry sevenfold or greater spreads between what they can cost and what they usually cost, which makes the sticker price meaningless without checking.
- 06
One demographic table that stands up, and one that does not
Seysara enrolled 2,002 subjects of whom 51% were adults and 15% were Black or African American — better representation than most of this register. Klisyri's population was 99% White and 87% male, which reflects who presents with actinic keratosis and still narrows what the evidence covers.
Disclosure scorecard
Not what is in the product — what the company publishes about it, and where. “Findable” means the concentration exists somewhere, such as a help-centre article, rather than on the page you buy from.
SCROLL THE TABLE SIDEWAYS
If you buy one
Tazorac
Worth buying for a specific person with a specific problem. Read who.